Nov 20, 2007
|
Vertex's Collaborator Merck Suspends Patient Enrollment in Clinical Trials of MK-0457 (VX-680) Pending Full Analysis of Clinical Data
|
|
Nov 05, 2007
|
Vertex Pharmaceuticals Announces Webcasts of its Presentations
at Two Investor Conferences
|
|
Nov 02, 2007
|
First Studies Demonstrating Greater than Sixty Percent Sustained Viral Response Rates with Half the Standard Treatment Duration in Genotype 1 Chronic Hepatitis C Patients
|
|
Oct 29, 2007
|
Vertex Pharmaceuticals Reports Third Quarter 2007 Financial Results and Provides Development Pipeline Update
|
|
Oct 09, 2007
|
Vertex Pharmaceuticals Announces the Date of its Third Quarter 2007 Financial Results Conference Call and Webcast
|
|
Sep 28, 2007
|
Vertex Announces Publication of Abstracts for Presentation at 58th AASLD Meeting
|
|
Sep 14, 2007
|
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
|
|
Sep 05, 2007
|
Vertex Pharmaceuticals Announces Webcast of its Presentation at the Bear Stearns 20th Annual Healthcare Conference
|
|
Jul 24, 2007
|
Vertex Pharmaceuticals Reports Second Quarter 2007 Financial Results and Provides Development Pipeline Update
|
|
Jul 09, 2007
|
Vertex Pharmaceuticals Announces the Date of its Second Quarter 2007 Financial Results Conference Call and Webcast
|
|
Jun 29, 2007
|
Vertex Pharmaceuticals Announces Two Executive Appointments
|
|
Jun 12, 2007
|
Vertex Pharmaceuticals Reports 2007 Pipeline Progress
|
|
Jun 01, 2007
|
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
|
|
May 31, 2007
|
Stockholders of Vertex Pharmaceuticals Re-elect Directors at Annual Meeting
|
|
May 17, 2007
|
Vertex Pharmaceuticals Announces Webcast of its Presentation at Citigroup's 2007 Global Healthcare Conference
|
|
Apr 30, 2007
|
Vertex Pharmaceuticals Reports First Quarter 2007 Financial Results
|
|
Apr 26, 2007
|
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
|
|
Apr 14, 2007
|
Interim Results Presented at EASL from PROVE 1 Clinical Trial of Investigational Drug Telaprevir in Patients with Genotype 1 Hepatitis C
|
|
Apr 11, 2007
|
Vertex Pharmaceuticals Announces New Data for Investigational HCV Protease Inhibitor Telaprevir to be Presented at 42nd Annual Meeting of the European Association for the Study of the Liver (EASL)
|
|
Mar 07, 2007
|
Vertex Pharmaceuticals Announces Webcasts of its Presentations at Two Investor Conferences
|
|